Catalyst Clinical Research, a provider of specialized clinical development solutions, acquired Genpro Research, a Massachusetts-based global clinical research organization with staff in the US, India, and Ireland.

Genpro is a next generation services and technology partner for the pharmaceutical, biotechnology, and medical devices industry with expertise in biometrics, medical writing, RWE, and AI enabled automation product development. Genpro will continue to be led by Sachin Marulkar and the existing management team.

The acquisition adds more than 120 team members in India with expertise in biometrics and medical writing. This enables clients to access Catalyst’s clinical research services, along with broader expertise in global time zones, new solutions, and access to innovative automation platforms.

Catalyst CEO Nick Dyer said, “We are hugely enthusiastic about the addition of Genpro to our family. We share the opportunity to expand our global footprint, broaden and deepen our services, and to use the AI platform to create value for ourselves and customers in a range of labor-intensive document creation processes. In addition, our approach to prioritizing culture and treating our teams like family are similar and will act as a critical foundation for our combined company as we move forward.”

Genpro CEO Sachin Marulkar said, “By joining Catalyst, we will continue to expand our biometrics, scientific reporting and technology offerings, have access to more opportunities globally, and provide our clients with additional products and services. We are excited to utilize the synergies in advancing our AI/ML technology platform to create beneficial new tools and improve the efficiency of clinical research. Catalyst is highly aligned with our purpose, values, and our relationship-driven focus. We look forward to stepping into these opportunities while still acting with the speed and flexibility our customers value and maintaining the collaborative culture that is so important to our employees.”